Poor
Not Aligned
Patient Risk:
Low
Summary
Multiple dosing, duration, pediatric dosing, renal/liver adjustment, discontinuation thresholds, and administration/storage details are asserted but are not supported by the provided label excerpts. Only the boxed warning claim (included elsewhere in the conversation) matches the supplied label text.
Category Scores
Accurate Statements
Alpha interferons, including PEGASYS (peginterferon alfa-2a), may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders.
BOXED WARNING (Risk of Serious Disorders): “Alpha interferons, including PEGASYS (peginterferon alfa-2a), may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders.”
Unsupported Statements
For chronic hepatitis C in adults, Pegasys (peginterferon alfa-2a) is dosed at 180 mcg subcutaneously once weekly.
The provided label excerpts do not include adult CHC dosing/strength/frequency.
For chronic hepatitis C in adults, Pegasys is typically given for 48 weeks in combination with ribavirin.
The provided label excerpts do not include CHC treatment duration or combination regimen details.
For children (ages 5+), Pegasys dosing is weight-based at 180 mcg per 1.73 m² of body surface area.
The provided label excerpts do not include pediatric CHC dosing guidance.
For children (ages 5+), the Pegasys dose is capped at 180 mcg.
The provided label excerpts do not include pediatric CHC dosing cap information.
For hepatitis B in adults, Pegasys is dosed at 180 mcg subcutaneously once weekly for 48 weeks.
The provided label excerpts do not include adult hepatitis B dosing/strength/frequency/duration.
For pediatric hepatitis B (ages 3+), Pegasys dosing is weight-based.
The provided label excerpts do not include pediatric hepatitis B dosing guidance.
For pediatric hepatitis B with body weight under 20 kg, the Pegasys dose is 5 mcg/kg once weekly for 48 weeks.
The provided label excerpts do not include the specific pediatric hepatitis B weight-band dosing scheme.
For pediatric hepatitis B with body weight 20-25 kg, the Pegasys dose is 10 mcg/kg once weekly for 48 weeks.
The provided label excerpts do not include the specific pediatric hepatitis B weight-band dosing scheme.
For pediatric hepatitis B with body weight over 25 kg, the Pegasys dose is fixed doses up to 180 mcg once weekly for 48 weeks.
The provided label excerpts do not include the specific pediatric hepatitis B weight-band dosing scheme.
If creatinine clearance is 30-59 mL/min, the Pegasys dose is reduced to 135 mcg weekly.
The provided label excerpts do not include renal impairment dosing adjustment details.
No adjustment is needed for mild liver impairment when using Pegasys.
The provided label excerpts do not include hepatic impairment dosing adjustment details.
Pegasys should be monitored closely in severe liver impairment and the dose should be reduced if severe.
The provided label excerpts do not include hepatic impairment dosing adjustment thresholds or instructions beyond hepatic failure warnings.
Pegasys should be discontinued if platelets drop below 50,000/mm³.
The provided label excerpts do not include specific platelet discontinuation thresholds.
Pegasys should be discontinued if neutrophils drop below 1,000/mm³.
The provided label excerpts do not include specific neutrophil discontinuation thresholds.
Pegasys is administered as a prefilled syringe injected under the skin in the abdomen or thigh.
The provided label excerpts do not include injection site instructions.
Pegasys injection sites should be rotated weekly.
The provided label excerpts do not include site rotation frequency instructions.
Pegasys should be stored refrigerated.
The provided label excerpts do not include storage and handling instructions.
Before use, Pegasys should be allowed to warm to room temperature.
The provided label excerpts do not include pre-use warming instructions.
Contradictions
Important Omissions
Concrete label-supported dosing/duration and population-specific regimens for CHC/CHB (adults and pediatrics) corresponding to the claims made.
Importance:
Moderate
Label-supported renal/hepatic impairment dosing adjustment rules and discontinuation thresholds for cytopenias.
Importance:
Moderate
Label-supported administration, injection site, rotation, and storage/warming instructions corresponding to the claims made.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most statements are unsupported by the provided label excerpts; however, none of the provided statements directly contradict the supplied boxed-warning and other warning excerpts. The lack of support is the primary risk for misinformation rather than direct label conflict.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Large portions of claimed dosing, duration, pediatric regimens, impairment adjustments, discontinuation thresholds, administration, and storage details are not supported by the prescribing information excerpts provided.
Suggested Improvement
Align each claim to a specific cited section/wording from the provided label text (or request additional label excerpts). Include only dosing/thresholds/administration/storage details that are explicitly present in the supplied FDA-approved label.